Reversal Agents for P-Glycoprotein-Mediated Multidrug Resistance

ABC Transporters and Multidrug Resistance

Volumn , Issue , 2009, Pages 239-259

  Morjani, Hamid ^a   Madoulet, Claudie ^b  

^a UFR Sciences Exactes et Naturelles   (France)

^b Centre de Recherche en STIC   (France)

Author keywords

Drug resistance reasons for cancer therapy failure; Immunization with synthetic P gp derived peptides; P gp activity modulation

Indexed keywords

EID: 84889432602     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470495131.ch8     Document Type: Chapter

References (116)

1. Gottesman MM. 1993. How cancer cells evade chemotherapy: Sixteenth Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res 53: 747-754.
2. Tsuruo T, Iida H, Tsukagoshi S, and Sakurai Y. 1981. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 41: 967-972.
3. Cano-Gauci DF and Riordan JR. 1987. Action of calcium antagonists on multidrug resistant cells. Specific cytotoxicity independent of increased cancer drug accumulation. Biochem Pharmacol 36: 2115-2123.
4. Silbermann MH, Boersma AW, Janssen AL, Scheper RJ, Herweijer H, and Nooter K. 1989. Effects of cyclosporin A and verapamil on the intracellular daunorubicin accumulation in Chinese hamster ovary cells with increasing levels of drug-resistance. Int J Cancer 44: 722-726.
5. Hait WN, Stein JM, Koletsky AJ, Harding MW, and Handschumacher RE. 1989. Activity of cyclosporin A and a non-immunosuppressive cyclosporin against multidrug resistant leukemic cell lines. Cancer Commun 1: 35-43.
6. Twentyman PR and Bleehen NM. 1991. Resistance modification by PSC-833, a novel non-immunosuppressive cyclosporin. Eur J Cancer 27: 1639-1642.
7. Boesch D, Gaveriaux C, Jachez B, Pourtier-Manzanedo A, Bollinger P, and Loor F. 1991. In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833. Cancer Res 51: 4226-4233.
8. Beck WT, Cirtain MC, Glover CJ, Felsted RL, and Safa AR. 1988. Effects of indole alkaloids on multidrug resistance and labeling of P-glycoprotein by a photoaffinity analog of vinblastine. Biochem Biophys Res Commun 153: 959-966.
9. Sonneveld P, Durie BG, Lokhorst HM, Marie JP, Solbu G, Suciu S et al. 1999. Modulation of multidrug-resistant multiple myeloma by cyclosporin. The Leukaemia Group of the EORTC and the HOVON. Lancet 340: 255-259.
10. List AF, Spier C, Greer J, Wolff S, Hutter J, Dorr R et al. 1993. Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia. J Clin Oncol 11: 1652-1660.
11. Sonneveld P, Suciu S, Weijermans P, Beksac M, Neuwirtova R, Solbu G et al. 2001. Cyclosporin A combined with vincristine, doxorubicin and dexamethasone (VAD) compared with VAD alone in patients with advanced refractory multiple myeloma: An EORTC-HOVON randomized phase III study (06914). Br J Haematol 115: 895-902.
12. List AF, Kopecky KJ, Willman CL, Head DR, Persons DL, Slovak ML et al. 2001. Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: A Southwest Oncology Group study. Blood 98: 3212-3220.
13. Boote DJ, Dennis IF, Twentyman PR, Osborne RJ, Laburte C, Hensel S et al. 1996. Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer. J Clin Oncol 14: 610-618.
14. Giaccone G, Linn SC, Welink J, Catimel G, Stieltjes H, van der Vijgh WJ et al. 1997. A dose-finding and pharmacokinetic study of reversal of multidrug resistance with SDZ PSC 833 in combination with doxorubicin in patients with solid tumors. Clin Cancer Res 3: 2005-2015.
15. Advani R, Saba HI, Tallman MS, Rowe JM, Wiernik PH, Ramek J et al. 1999. Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Valspodar). Blood 93: 787-795.
16. Fracasso PM, Westervelt P, Fears CL, Rosen DM, Zuhowski EG, Cazenave LA et al. 2000. Phase I study of paclitaxel in combination with a multidrug resistance modulator, PSC 833 (Valspodar), in refractory malignancies. J Clin Oncol 18: 1124-1134.
17. Baer MR, George SL, Dodge RK, O'Loughlin KL, Minderman H, Caligiuri MA et al. 2002. Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. Blood 100: 1224-1232.
18. Bates SE, Bakke S, Kang M, Robey RW, Zhai S, Thambi P et al. 2004. A phase I/II study of infusional vinblastine with the P-glycoprotein antagonist valspodar (PSC 833) in renal cell carcinoma. Clin Cancer Res 10: 4724-4733.
19. Thomas H and Coley HM. 2003. Overcoming multidrug resistance in cancer: An update on the clinical strategy of inhibiting P-glycoprotein. Cancer Control 10: 159-165.
20. Burchenal JH, Robinson E, Johnston SF et al. 1950. The induction of resistance to 4-amino-N10-methyl-pteroylglutaminic acid in a strain of transmitted mouse leukemia. Science 111: 116-117.
21. Dano K. 1973. Active outward transport of daunomycin in resistant Ehrlich ascites tumor cells. Biochim Biophys Acta 323: 466-483.
22. Juliano RL and Ling V. 1976. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biophys Biochim Acta 455: 152-162.
23. Ueda K, Clark DP, Chen CJ, Roninson IB, Gottesman MM, Pastan I et al. 1987. The human multidrug resistance (mdr1) gene. cDNA cloning and transcription initiation. J Biol Chem 262: 505-508.
24. Riordan JR and Ling V. 1979. Purification of P-glycoprotein from plasma membrane vesicles of Chinese hamster ovary cell mutants with reduced colchicine permeability. J Biol Chem 254: 12701-12705.
25. Riou JF, Naudin A, and Lavelle F. 1992. Effects of Taxotere on murine and human tumor cell lines. Biochem Biophys Res Commun 187: 164-170.
26. Greenberger LM, Lothstein L, Williams SS, and Horwitz SB. 1988. Distinct P-glycoprotein precursors are overproduced in independently isolated drug-resistant cell lines. Proc Natl Acad Sci USA 85: 3762-3766.
27. Leier I, Jedlitschky G, Buchholz U, Cole SPC, Deeley RG, and Keppler D. 1994. The MRP gene encodes an ATP-dependent export pump for leukotriene C4 and structurally related conjugates. J Biol Chem 269: 27807-27810.
28. Honjo Y, Hrycyna CA, Yan QW, Medina-Perez WY, Robey RW, van de Laar A et al. 2001. Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells. Cancer Res 61: 6635-6639.
29. Wattel E, Solary E, Hecquet B, Caillot D, Ifrah N, Brion A et al. 1999. Quinine improves results of intensive chemotherapy (IC) in myelodysplastic syndromes (MDS) expressing P-glycoprotein (PGP). Updated results of a randomized study. Groupe Français des Myélodysplasies (GFM) and Groupe GOELAMS. Adv Exp Med Biol 457: 35-46.
30. Daenen S, van der Holt B, Verhoef GE, Löwenberg B, Wijermans PW, Huijgens PC et al. 2004. Addition of cyclosporin A to the combination of mitoxantrone and etoposide to overcome resistance to chemotherapy in refractory or relapsing acute myeloid leukaemia: A randomised phase II trial from HOVON, the Dutch-Belgian Haemato-Oncology Working Group for adults. Leuk Res 28: 1057-1067.
31. Höllt V, Kouba M, Dietel M, and Vogt G. 1992. Stereoisomers of calcium antagonists which differ markedly in their potencies as calcium blockers are equally effective in modulating drug transport by P-glycoprotein. Biochem Pharmacol 43: 2601-2608.
32. Robert J and Jarry C. 2003. Multidrug resistance reversal agents. J Med Chem 46: 4805-4817.
33. Szakács G, Paterson JK, Ludwig JA, Booth-Genthe C, and Gottesman MM. 2006. Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5: 219-234.
34. Seelig A and Gatlik-Landwojtowicz E. 2005. Inhibitors of multidrug efflux transporters: Their membrane and protein interactions. Mini Rev Med Chem 5: 135-151.
35. Twentyman PR. 1992. Cyclosporins as drug resistance modifiers. Biochem Pharmacol 43: 109-117.
36. Tanigawara Y, Okamura N, Hirai M, Yasuhara M, Ueda K, Kioka N et al. 1992. Transport of digoxin by human P-glycoprotein expressed in a porcine kidney epithelial cell line (LLC-PK1). JPharmacol Exp Ther 263: 840-845.
37. Wattel E, Solary E, Hecquet B, Caillot D, Ifrah N, Brion A et al. 1998. Quinine improves the results of intensive chemotherapy in myelodysplastic syndromes expressing P glycoprotein: Results of a randomized study. Br J Haematol 102: 1015-1024.
38. Hofmann J, Wolf A, Spitaler M, Böck G, Drach J, Ludescher C et al. 1992. Reversal of multidrug resistance by B859-35, a metabolite of B859-35, niguldipine, verapamil and nitrendipine. J Cancer Res Clin Oncol 118: 361-366.
39. Minderman H, O'Loughlin KL, Pendyala L, and Baer MR. 2004. VX-710 (birico-dar) increases drug retention and enhances chemosensitivity in resistant cells overexpressing P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein. Clin Cancer Res 10: 1826-1834.
40. Hyafil F, Vergely C, Du Vignaud P, and Grand-Perret T. 1993. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res 53: 4595-4602.
41. Zhou DC, Simonin G, Faussat AM, Zittoun R, and Marie JP. 1997. Effect of the multidrug inhibitor GG918 on drug sensitivity of human leukemic cells. Leukemia 11: 1516-1522.
42. Dantzig AH, Shepard RL, Pratt SE, Tabas LB, Lander PA, Ma L et al. 2004. Evaluation of the binding of the tricyclic isoxazole photoaffinity label LY475776 to multidrug resistance associated protein 1 (MRP1) orthologs and several ATP. binding cassette (ABC) drug transporters. Biochem Pharmacol 67: 1111-1121.
43. Shepard RL, Cao J, Starling JJ, and Dantzig AH. 2003. Modulation of P-glycoprotein but not MRP1-or BCRP-mediated drug resistance by LY335979. Int J Cancer 103: 121-125.
44. Tang R, Faussat AM, Perrot JY, Marjanovic Z, Cohen S, Storme T et al. 2008. Zosuquidar restores drug sensitivity in P-glycoprotein expressing acute myeloid leukemia (AML). BMC Cancer 8: 51.
45. Martin C, Berridge G, Mistry P, Higgins C, Charlton P, and Callaghan R. 1999. The molecular interaction of the high affinity reversal agent XR9576 with P-glycoprotein. Br J Pharmacol 128: 403-411.
46. Walker J, Martin C, and Callaghan R. 2004. Inhibition of P-glycoprotein function by XR9576 in a solid tumour model can restore anticancer drug efficacy. Eur J Cancer 40: 594-605.
47. Evers R, Kool M, Smith AJ, van Deemter L, de Haas M, and Borst P. 2000. Inhibitory effect of the reversal agents V-104, GF120918 and Pluronic L61 on MDR1 Pgp-, MRP1-and MRP2-mediated transport. Br J Cancer 83: 366-374.
48. van Zuylen L, Sparreboom A, van der Gaast A, van der Burg ME, van Beurden V, Bol CJ et al. 2000. The orally administered P-glycoprotein inhibitor R101933 does not alter the plasma pharmacokinetics of docetaxel. Clin Cancer Res 6: 1365-1371.
49. van Zuylen L, Sparreboom A, van der Gaast A, Nooter K, Eskens FA, Brouwer E et al. 2002. Disposition of docetaxel in the presence of P-glycoprotein inhibition by intravenous administration of R101933. Eur J Cancer 38: 1090-1099.
50. Pierré A, Dunn TA, Kraus-Berthier L, Léonce S, Saint-Dizier D, Régnier G et al. 1992. In vitro and in vivo circumvention of multidrug resistance by Servier 9788, a novel triazinoaminopiperidine derivative. Invest New Drugs 10: 137-148.
51. Punt CJ, Voest EE, Tueni E, Van Oosterom AT, Backx A, De Mulder PH et al. 1997. Phase IB study of doxorubicin in combination with the multidrug resistance reversing agent S9788 in advanced colorectal and renal cell cancer. Br J Cancer 76: 1376-1381.
52. Vastag B. 2000. Almost serendipity: Alcoholism drug reverses drug resistance in vitro. J Natl Cancer Inst 92: 864-865.
53. Venne A, Li S, Mandeville R, Kabanov A, and Alakhov V. 1996. Hypersensitizing effect of pluronic L61 on cytotoxic activity, transport, and subcellular distribution of doxorubicin in multiple drug-resistant cells. Cancer Res 56: 3626-3629.
54. Ozols RF, Cunnion RE, Klecker RW Jr, Hamilton TC, Ostchega Y, Parrillo JE et al. 1987. Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients. J Clin Oncol 5: 641-647.
55. Dalton WS, Grogan TM, Meltzer PS, Scheper RJ, Durie BG, Taylor CW et al. 1989. Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: Detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J Clin Oncol 7: 1578-1579.
56. Salmon SE, Dalton WS, Grogan TM, Plezia P, Lehnert M, Roe DJ et al. 1991. Multidrug-resistant myeloma: Laboratory and clinical effects of verapamil as a chemosensitizer. Blood 78: 44-50.
57. Dalton WS, Crowley JJ, Salmon SS, Grogan TM, Laufman LR, Weiss GR et al. 1995. A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma. A Southwest Oncology Group study. Cancer 75: 815-820.
58. Demicheli R, Jirillo A, Bonciarelli G, Lonardi F, Balli M, and Bandello A. 1989. 4'-Epidoxorubicin plus verapamil in anthracycline-refractory cancer patients. Tumori 75: 245-247.
59. Langenbuch T, Mross K, Jonat W, and Hossfeld DK. 1990. A phase II study of intensive-dose epirubicin/verapamil as induction therapy followed by intensive-dose ifosfamide for advanced breast cancer. Cancer Chemother Pharmacol 26: 93-96.
60. Mross K, Bohn C, Edler L, Jonat W, Queisser W, Heidemann E et al. 1993. Randomized phase II study of single-agent epirubicin ± verapamil in patients with advanced metastatic breast cancer. An AIO clinical trial. Arbeitsgemeinschaft Internistische Onkologie of the German Cancer Society. Ann Oncol 4: 45-50.
61. Cairo MS, Siegel S, Anas N, and Sender L. 1989. Clinical trial of continuous infusion verapamil, bolus vinblastine, and continuous infusion VP-16 in drug-resistant pediatric tumors. Cancer Res 49: 1063-1066.
62. Millward MJ, Cantwell BM, Lien EA, Carmichael J, and Harris AL. 1992. Intermittent high-dose tamoxifen as a potential modifier of multidrug resistance. Eur J Cancer 28A: 805-810.
63. Belpomme D, Gauthier S, Pujade-Lauraine E, Facchini T, Goudier MJ, Krakowski I et al. 2000. Verapamil increases the survival of patients with anthracycline-resistant metastatic breast carcinoma. Ann Oncol 11: 1471-1476.
64. Bissett D, Kerr DJ, Cassidy J, Meredith P, Traugott U, and Kaye SB. 1991. Phase I and pharmacokinetic study of D-verapamil and doxorubicin. Br J Cancer 64: 1168-1171.
65. Wilson WH, Bates SE, Fojo A, Bryant G, Zhan Z, Regis J et al. 1995. Controlled trial of dexverapamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy. J Clin Oncol 13: 1995-2004.
66. Lehnert M, Mross K, Schueller J, Thuerlimann B, Kroeger N, and Kupper H. 1998. Phase II trial of dexverapamil and epirubicin in patients with non-responsive metastatic breast cancer. Br J Cancer 77: 1155-1163.
67. Scheithauer W, Kornek G, Kastner J, Raderer M, Locker G, Depisch D et al. 1993. Phase II study of D-verapamil and doxorubicin in patients with metastatic colorectal cancer. Eur J Cancer 29A: 2337-2338.
68. Motzer RJ, Lyn P, Fischer P, Lianes P, Ngo RL, Cordon-Cardo C et al. 1995. Phase I/II trial of dexverapamil plus vinblastine for patients with advanced renal cell carcinoma. J Clin Oncol 13: 1958-1965.
69. Warner E, Hedley D, Andrulis I, Myers R, Trudeau M, Warr D et al. 1998. Phase II study of dexverapamil plus anthracycline in patients with metastatic breast cancer who have progressed on the same anthracycline regimen. Clin Cancer Res 4: 1451-1457.
70. Wishart GC, Bissett D, Paul J, Jodrell D, Harnett A, Habeshaw T et al. 1994. Quinidine as a resistance modulator of epirubicin in advanced breast cancer: Mature results of a placebo-controlled randomized trial. J Clin Oncol 12: 1771-1777.
71. Bennis S, Ichas F, and Robert J. 1995. Differential effects of verapamil and quinine on the reversal of doxorubicin resistance in a human leukemia cell line. Int J Cancer 62: 283-290.
72. Belhoussine R, Morjani H, Lahlil R, and Manfait M. 1997. Evidence for reversal of multidrug resistance by quinine in LR73 cells without alteration of nuclear pirarubicin uptake and down-regulation of mdr1 gene expression. Int J Cancer 73: 600-606.
73. Solary E, Caillot D, Chauffert B, Casasnovas RO, Dumas M, Maynadie M et al. 1992. Feasibility of using quinine, a potential multidrug resistance-reversing agent, in combination with mitoxantrone and cytarabine for the treatment of acute leukemia. J Clin Oncol 10: 1730-1736.
74. Solary E, Witz B, Caillot D, Moreau P, Desablens B, Cahn JY, Sadoun A, Pignon B et al. 1996. Combination of quinine as a potential reversing agent with mito-xantrone and cytarabine for the treatment of acute leukemias: A randomized multicenter study. Blood 88: 1198-1205.
75. Miller TP, Chase EM, Dorr R, Dalton WS, Lam KS, and Salmon SE. 1998. A phase I/II trial of paclitaxel for non-Hodgkin's lymphoma followed by paclitaxel plus quinine in drug-resistant disease. Anti-cancer Drugs 9: 135-140.
76. Solary E Mannone L, Moreau D, Caillot D, Casasnovas RO, Guy H et al. 2000. Phase I study of cinchonine, a multidrug resistance reversing agent, combined with the CHVP regimen in relapsed and refractory lymphoproliferative syndromes. Leukemia 14: 2085-2094.
77. Saeki T, Ueda K, Tanigawara Y, Hori R, and Komano T. 1993. Human P-glycoprotein transports cyclosporin A and FK506. J Biol Chem 268: 6077-6080.
78. Shirai A, Naito M, Tatsuta T, Dong J, Hanaoka K, Mikami K et al. 1994. Transport of cyclosporin A across the brain capillary endothelial cell monolayer by P-glycoprotein. Biochim Biophys Acta 1222: 400-404.
79. Schramm U, Fricker G, Wenger R, and Miller DS. 1995. P-glycoprotein-mediated secretion of a fluorescent cyclosporin analogue by teleost renal proximal tubules. Am J Physiol 268: 46-52.
80. Stein WD. 1997. Kinetics of the multidrug transporter (P-glycoprotein) and its reversal. Physiol Rev 77: 545-590.
81. Litman T, Zeuthen T, Skovsgaard T, and Stein WD. 1997. Structure-activity relationships of P-glycoprotein interacting drugs: Kinetic characterization of their effects on ATPase activity. Biochim Biophys Acta 1361: 159-168.
82. Merlin JL, Guerci A, Marchal S, Missoum N, Ramacci C, Humbert JC et al. 1994. Comparative evaluation of S9788, verapamil, and cyclosporine A in K562 human leukemia cell lines and in P-glycoprotein-expressing samples from patients with hematologic malignancies. Blood 84: 262-269.
83. Merlin JL, Guerci AP, Marchal S, Bour C, Colosetti P, Kataki A et al. 1998. Influence of SDZ-PSC833 on daunorubicin intracellular accumulation in bone marrow specimens from patients with acute myeloid leukaemia. Br J Haematol 103: 480-487.
84. Legrand O, Simonin G, Perrot JY, Zittoun R, and Marie JP. 1998. Pgp and MRP activities using calcein-AM are prognostic factors in adult acute myeloid leukemia patients. Blood 91: 4480-4488.
85. Legrand O, Simonin G, Beauchamp-Nicoud A, Zittoun R, and Marie JP. 1999. Simultaneous activity of MRP1 and Pgp is correlated with in vitro resistance to daunorubicin and with in vivo resistance in adult acute myeloid leukemia. Blood 94: 1046-1056.
86. Twentyman PR. 1992. Cyclosporins as drug resistance modifiers. Biochem Pharmacol 43: 109-117.
87. Leonard GD, Fojo T, and Bates SE. 2003. The role of ABC transporters in clinical practice. Oncologist 8: 411-424.
88. Bates SE. 2002. Solving the problems of multidrug-resistance: ABC transporters in clinical oncology. In ABC Proteins: From Bacteria to Man Holland IB, ed. IB Holland, SPC Cole, K Kuchler, and CF Higgins, 359-391. London: Elsevier Science.
89. Beketic-Oreskovic L, Duran GE, Chen G, Dumontet C, and Sikic BI. 1995. Decreased mutation rate for cellular resistance to doxorubicin and suppression of mdr1 gene activation by the cyclosporin PSC 833. J Natl Cancer Inst 87: 1593-1602.
90. Cocker HA, Tiffin N, Pritchard-Jones K, Pinkerton CR, and Kelland LR. 2001. In vitro prevention of the emergence of multidrug resistance in a pediatric rhabdomyosarcoma cell line. Clin Cancer Res 7: 3193-3198.
91. Germann UA, Shlyakhter D, Mason VS, Zelle RE, Duffy JP, Galullo V et al. 1997. Cellular and biochemical characterization of VX-710 as a chemosensitizer: Reversal of P-glycoprotein-mediated multidrug resistance in vitro. Anti-cancer Drugs 8: 125-140.
92. Germann UA, Ford PJ, Shlyakhter D, Mason VS, and Harding MW. 1997. Chemosensitization and drug accumulation effects of VX-710, verapamil, cyclosporin A, MS-209 and GF120918 in multidrug resistant HL60/ADR cells expressing the multidrug resistance-associated protein MRP. Anti-cancer Drugs 8: 141-155.
93. Peck RA, Hewett J, Harding MW, Wang YM, Chaturvedi PR, Bhatnagar A et al. 2001. Phase I and pharmacokinetic study of the novel MDR1 and MRP1 inhibitor biricodar administered alone and in combination with doxorubicin. J Clin Oncol 19: 3130-3141.
94. De Bruin M, Miyake K, Litman T, Robey R, and Bates SE. 1999. Reversal of resistance by GF120918 in cell lines expressing the ABC half-transporter, MXR. Cancer Lett 146: 117-126.
95. Sparreboom A, Planting AS, Jewell RC, van der Burg ME, van der Gaast A, de Bruijn P et al. 1999. Clinical pharmacokinetics of doxorubicin in combination with GF120918, a potent inhibitor of MDR1 P-glycoprotein. Anti-cancer Drugs 10: 719-728.
96. Kruijtzer CM, Beijnen JH, Rosing H, ten Bokkel Huinink WW, Schot M, Jewell RC et al. 2002. Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. J Clin Oncol 20: 2943-2950.
97. Malingré MM, Beijnen JH, Rosing H, Koopman FJ, Jewell RC, Paul EM et al. 2001. Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients. Br J Cancer 84: 42-47.
98. Dantzig AH, Law KL, Cao J, and Starling JJ. 2001. Reversal of multidrug resistance by the P-glycoprotein modulator, LY335979, from the bench to the clinic. Curr Med Chem 8: 39-50.
99. Rubin EH, de Alwis DP, Pouliquen I, Green L, Marder P, Lin Y et al. 2002. A phase I trial of a potent P-glycoprotein inhibitor, Zosuquidar. 3HCl trihydrochloride (LY335979), administered orally in combination with doxorubicin in patients with advanced malignancies. Clin Cancer Res 8: 3710-3717.
100. Gerrard G, Payne E, Baker RJ, Jones DT, Potter M, Prentice HG et al. 2004. Clinical effects and P-glycoprotein inhibition in patients with acute myeloid leukemia treated with zosuquidar trihydrochloride, daunorubicin and cytarabine. Haematologica 89: 782-790.
101. Mistry P, Stewart AJ, Dangerfield W, Okiji S, Liddle C, Bootle D et al. 2001. In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576. Cancer Res 61: 749-758.
102. Stewart A, Steiner J, Mellows G, Laguda B, Norris D, and Bevan P. 2000. Phase I trial of XR9576 in healthy volunteers demonstrates modulation of P-glycoprotein in CD56+ lymphocytes after oral and intravenous administration. Clin Cancer Res 6: 4186-4191.
103. Pusztai L, Wagner P, Ibrahim N, Rivera E, Theriault R, Booser D et al. 2005. Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma. Cancer 104: 682-691.
104. Hamada H and Tsuruo T. 1986. Functional role for the 170-to 180-kDa glycoprotein specific to drug-resistant tumor cells as revealed by monoclonal antibodies. Proc Natl Acad Sci USA 83: 7785-7789.
105. Mickisch GH, Pai LH, Gottesman MM, and Pastan I. 1992. Monoclonal antibodies MRK16 reverses the multidrug resistance of multidrug-resistance transgenic mice. Cancer Res 52: 4427-4432.
106. Pawlak-Roblin C, Tosi PF, Perrin L, Devy J, Ventéo L, Albert P et al. 2004. Inhibition of multidrug resistance by immunisation with synthetic P-glycoprotein-derived peptides. Eur J Cancer 40: 606-613.
107. Perrin L, Gatouillat G, Balasse E, Odot J, Nicolau C, Tosi PF et al. 2007. Induction of autoantibodies to murine P-glycoprotein: Consequences on drug sensitivity in MDR cancer cells and on the expression of mdr genes in organs. Biochem Biophys Res Commun 358: 325-330.
108. Gatouillat G, Odot J, Balasse E, Nicolau C, Tosi PF, Hickman DT et al. 2007. Immunization with liposome-anchored pegylated peptides modulates doxorubicin sensitivity in P-glycoprotein-expressing P388 cells. Cancer Lett 257: 165-171.
109. Madoulet C, Perrin L, Tosi PF, and Albert P. 2006. Anti-tumor immunotherapy against multidrug resistance. Ann Pharm Fr 64: 87-96.
110. Xu D, Kang H, Fisher M, and Juliano RL. 2004. Strategies for inhibition of MDR1 gene expression. Mol Pharmacol 66: 268-275.
111. Pichler A, Zelcer N, Prior JL, Kuil AJ, and Piwnica-Worms D. 2005. In vivo RNA interference-mediated ablation of MDR1 P-glycoprotein. Clin Cancer Res 11: 4487-4494.
112. Szakács G, Annereau JP, Lababidi S, Shankavaram U, Arciello A, Bussey KJ et al. 2004. Predicting drug sensitivity and resistance: Profiling ABC transporter genes in cancer cells. Cancer Cell 6: 129-137.
113. Perego P, De Cesare M, De Isabella P, Carenini N, Beggiolin G, Pezzoni G et al. 2001. A novel 7-modified camptothecin analog overcomes breast cancer resistance protein-associated resistance in a mitoxantrone-selected colon carcinoma cell line. Cancer Res 61: 6034-6037.
114. Lampidis TJ, Kolonias D, Podona T, Israel M, Safa AR, Lothstein L et al. 1997. Circumvention of P-GP MDR as a function of anthracycline lipophilicity and charge. Biochemistry 36: 2679-2685.
115. Byrne JL, Dasgupta E, Pallis M, Turzanski J, Forman K, Mitchell D et al. 1999. Early allogeneic transplantation for refractory or relapsed acute leukaemia following remission induction with FLAG. Leukemia 13: 786-791.
116. Pallis M and Russell N. 2004. Strategies for overcoming p-glycoprotein-mediated drug resistance in acute myeloblastic leukaemia. Leukemia 18: 1927-1930.